


Curriculum Vitae



1. 姓名：翁啓昌
2. 工作單位：長庚大學
3. 職稱：助理教授
4. 科別：醫學院 醫學影像暨放射科學系
5. 辦公室地址：333 桃園市龜山區文化一路 259 號第一醫學大樓 1221 室
6. 辦公室電話/傳真：(03)2118800 轉 5388 / (03)2115563
7. 電子信箱：ccweng@mail.cgu.edu.tw
8. 個人網站： https://www.researchgate.net/profile/Chi_Chang_Weng
9. 研究領域：核醫藥物、放射化學、輻射劑量
10. 工作經歷：
 - (1) 2019.02~迄今 長庚大學醫學影像暨放射科學系 專任助理教授
 - (2) 2016.06-2018.11 美國賓州大學放射科學部 研究員
11. 學歷：
 - (1) 2017.06 國立清華大學 生醫工程與環境科學系 博士
 - (2) 2010.06 長庚大學 醫學物理暨影像科學所 碩士
 - (3) 2005.06 長庚大學 醫事技術學系放射組 學士
12. 殊榮(獲獎消息)
 - 2018.06 SNMMI Poster Award
 - 2010.09 WMIC Travel Stipend
13. 代表論文：
 - Wey SP, **Weng CC**, Lin KJ, Yao CH, Yen TC, Kung HF, Skovronsky D, Kung MP. Validation of an ^{18}F -labeled biphenylalkyne as a positron emission tomography imaging agent for β -amyloid plaques. Nuclear Medicine and Biology 2009;36:411-417.
 - Yao CH, Lin KJ, **Weng CC**, Hsiao IT, Ting YS, Yen TC, Jan TR, Skovronsky D, Kung MP, Wey SP. GMP-compliant automated synthesis of [^{18}F]AV-45 (Florbetapir F 18) for imaging β -amyloid plaques in human brain. Applied Radiation and Isotopes 2010;68(12):2293-2297.
 - **Weng CC**, Chen ZA, Chao KT, Ee TW, Lin KJ, Chan MH, Hsiao T, Yen TC, Kung MP, Hsu CH, Wey SP. Quantitative analysis of the therapeutic effect of magnolol on MPTP-induced mouse model of Parkinson's disease using in vivo ^{18}F -9-fluoropropyl-(+)-dihydrotetabenazine PET imaging. PloS one. 2017 Mar 3;12(3):e0173503.
 - **Weng CC**, Huang SL, Chen ZA, Lin KJ, Hsiao T, Yen TC, Kung MP, Wey SP,

Hsu CH. [^{18}F] FP-(+)-DTBZ PET study in a lactacystin-treated rat model of Parkinson disease. *Annals of Nuclear Medicine*. 2017 Apr 27:1-8.

- Sellmyer MA, Lee I, Hou C, Weng CC, Li S, Lieberman BP, Zeng C, Mankoff DA, Mach RH. Bacterial infection imaging with [^{18}F] fluoropropyl-trimethoprim. *Proceedings of the National Academy of Sciences*. 2017 Aug 1;114(31):8372-7.

14. 學會或專業認證：

- (1) 2007 輻射防護師及格，962 輻試及字第 110057 號
- (2) 2005 醫事放射證書，放字第 004770 號

15. 所有發表期刊論文：

- (1) Zeng C, Weng CC, Schneider ME, Puentes L, Riad A, Xu K, Makvandi M, Jin L, Hawkins WG, Mach RH. TMEM97 and PGRMC1 do not mediate sigma-2 ligand-induced cell death. *Cell death discovery*. 2019 Jan 28;5(1):58.
- (2) Elmi A, Makvandi M, Weng CC, Hou C, Clark AS, Mach RH, Mankoff DA. Cell-proliferation imaging for monitoring response to CDK4/6 inhibition combined with endocrine-therapy in breast cancer: Comparison of [^{18}F] FLT and [^{18}F] ISO-1 PET/CT. *Clinical Cancer Research*. 2019 Jan 1;clincanres-2769.
- (3) Riad A, Zeng C, Weng CC, Winters H, Xu K, Makvandi M, Metz T, Carlin S, Mach RH. Sigma-2 Receptor/TMEM97 and PGRMC-1 Increase the Rate of Internalization of LDL by LDL Receptor through the Formation of a Ternary Complex. *Scientific reports*. 2018 Nov 15;8(1):16845.
- (4) Reilly SW, Puentes LN, Schmitz A, Hsieh CJ, Weng CC, Hou C, Li S, Kuo YM, Padakanti P, Lee H, Riad AA. Synthesis and evaluation of an AZD2461 [^{18}F] PET probe in non-human primates reveals the PARP-1 inhibitor to be non-blood-brain barrier penetrant. *Bioorganic chemistry*. 2019 Mar 1;83:242-9.
- (5) Reilly SW, Puentes L, Wilson K, Hsieh CJ, Weng CC, Makvandi M, Mach RH. Examination of Diazaspiro Cores as Piperazine Bioisosteres in the Olaparib Framework Shows Reduced DNA Damage and Cytotoxicity. *Journal of medicinal chemistry*. 2018 Jun 1.
- (6) Makvandi M, Pantel A, Schwartz L, Schubert E, Xu K, Hsieh CJ, Hou C, Kim H, Weng CC, Winters H, Doot R. A PET imaging agent for evaluating PARP-1 expression in ovarian cancer. *The Journal of clinical investigation*. 2018 Mar 6.
- (7) Reilly SW, Griffin S, Taylor M, Sahlholm K, Weng CC, Xu K, Jacome DA,

Luedtke RR, Mach RH. Highly Selective Dopamine D3 Receptor Antagonists with Arylated Diazaspiro Alkane Cores. *Journal of Medicinal Chemistry*. 2017 Nov 10.

- (8) Hou C, Hsieh CJ, Li S, Lee H, Graham TJ, Xu K, Weng CC, Doot RK, Chu W, Chakraborty SK, Dugan LL. Development of a PET Radiotracer for Imaging Elevated Levels of Superoxide in Neuroinflammation. *ACS Chemical Neuroscience*. 2017 Nov 3;9(3):578-586.
- (9) Sellmyer MA, Lee I, Hou C, Weng CC, Li S, Lieberman BP, Zeng C, Mankoff DA, Mach RH. Bacterial infection imaging with [^{18}F] fluoropropyl-trimethoprim. *Proceedings of the National Academy of Sciences*. 2017 Aug 1;114(31):8372-7.
- (10) Weng CC, Huang SL, Chen ZA, Lin KJ, Hsiao T, Yen TC, Kung MP, Wey SP, Hsu CH. [^{18}F] FP-(+)-DTBZ PET study in a lactacystin-treated rat model of Parkinson disease. *Annals of Nuclear Medicine*. 2017 Apr 27:1-8.
- (11) Weng CC, Chen ZA, Chao KT, Ee TW, Lin KJ, Chan MH, Hsiao T, Yen TC, Kung MP, Hsu CH, Wey SP. Quantitative analysis of the therapeutic effect of magnolol on MPTP-induced mouse model of Parkinson's disease using in vivo ^{18}F -9-fluoropropyl-(+)-dihydrotetrabenazine PET imaging. *PloS one*. 2017 Mar 3;12(3):e0173503.
- (12) Kung MP, Weng CC, Lin KJ, Hsiao IT, Yen TC, Wey SP. Amyloid plaque imaging from IMPY/SPECT to AV-45/PET. *Chang Gung Med Journal* 2012;35(3):211-218.
- (13) Yao CH, Lin KJ, Weng CC, Hsiao IT, Ting YS, Yen TC, Jan TR, Skovronsky D, Kung MP, Wey SP. GMP-compliant automated synthesis of [^{18}F]AV-45 (Florbetapir F 18) for imaging β -amyloid plaques in human brain. *Applied Radiation and Isotopes* 2010;68(12):2293-2297.
- (14) Wey SP, Weng CC, Lin KJ, Yao CH, Yen TC, Kung HF, Skovronsky D, Kung MP. Validation of an ^{18}F -labeled biphenylalkyne as a positron emission tomography imaging agent for β -amyloid plaques. *Nuclear Medicine and Biology* 2009;36:411-417. (Co-first author)